TCW Group boosts Accuray (ARAY) stake to 13.7% through loan-linked warrants
The TCW Group, Inc. has increased its beneficial ownership in Accuray Incorporated (ARAY) to approximately 13.7% through warrants linked to a Delayed Draw Term Loan. This stake, totaling 18,942,059 shares, includes common stock purchase warrants exercisable at various prices and terms running until May 19, 2033. The warrants were issued as a condition for TCW to provide financing to Accuray, with no separate consideration paid for them.
TCW Group (NASDAQ: ARAY) affiliates receive Accuray warrants tied to term loan
Affiliates of TCW Group received warrants to purchase 18,942,059 shares of Accuray common stock as part of a financing agreement. These warrants, with exercise prices ranging from $0.01 to $1.50 per share and expiring in May 2033, were issued as consideration for a Delayed Draw Term Loan. This transaction, classified as a restructuring-related entry (code J), clarifies institutional warrant holdings rather than open-market trading.
Radiotherapy Market Key Players | Siemens Healthineers AG, Accuray Incorporated, Elekta AB etc.
The global radiotherapy market is projected to reach US$ 10,170.80 million by 2028, growing at a CAGR of 5.9% from 2021 to 2028, driven by the increasing global cancer burden and technological advancements. The market is undergoing transformation due to precision oncology, AI, and advanced imaging, with key trends including precision radiotherapy, AI-driven planning, and expanding proton therapy. North America leads the market, while Asia-Pacific is expected to be the fastest-growing region.
Accuray brings AI in radiotherapy to ESTRO stage focusing on clinical performance and ethics
Accuray will present on the integration of artificial intelligence in radiotherapy at the ESTRO event, covering clinical performance, legal frameworks, and ethical considerations. The discussion aims to explore how AI can enhance patient care while addressing regulatory and ethical challenges. This follows Accuray's recent clinical success with its Radixact system in Myanmar and demonstrations of CyberKnife and helical platforms at previous conferences.
Accuray and the University of Wisconsin-Madison Announce Master Research Agreement to Improve Personalized Care for Patients with Cancer – Company Announcement
Accuray and the University of Wisconsin School of Medicine and Public Health (UW SMPH) have announced a new 10-year strategic collaboration. This Master Research Agreement aims to advance personalized cancer treatments using Accuray's Stellar™ adaptive radiation therapy platform. The partnership builds on a long history of innovation, including the development of the TomoTherapy® System, and will focus on clinical research, education, training, and adaptive therapies.
10-year Accuray–UW alliance aims to tailor radiation for cancer patients
Accuray and the University of Wisconsin School of Medicine and Public Health have announced a 10-year Master Research Agreement to advance personalized cancer care using Accuray's Stellar adaptive radiation therapy platform. This collaboration will support clinical research, education, training, and the development of next-generation adaptive radiotherapy. The partnership builds on their history, which includes UW-invented technology commercialized as Accuray's TomoTherapy System.
News Flash: 2 Analysts Think Accuray Incorporated (NASDAQ:ARAY) Earnings Are Under Threat
This article highlights that two analysts are concerned about Accuray Incorporated's (NASDAQ:ARAY) upcoming earnings. These concerns are rooted in recent financial performance and market conditions, suggesting potential challenges for the company's profitability. Investors are advised to consider these analyst warnings as they evaluate their position in ARAY.
Accuray Shares Fall After Jefferies Downgrade
Accuray (ARAY) shares dropped following a downgrade from Jefferies. Analyst Michael Petusky downgraded the stock to Hold from Buy and reduced the price target significantly from $8.50 to $3.00, citing increased business risk. Petusky highlighted concerns about competition and Accuray's ability to compete effectively against larger firms while also noting potential downside risk for fiscal 2026 sales and earnings guidance.
Jefferies downgrades Accuray stock rating on guidance withdrawal By Investing.com
Jefferies downgraded Accuray Inc. (NASDAQ:ARAY) to Hold from Buy and cut its price target significantly, following the company's fiscal third-quarter miss and withdrawal of full-year guidance. Accuray cited geopolitical uncertainties in the Middle East causing shipment delays and ongoing issues with its China joint venture. Another firm, BTIG, also downgraded Accuray, highlighting persistent revenue challenges and the withdrawal of financial guidance for fiscal year 2026.
Accuray Slides As Insider Purchases Lose Another US$95k
Accuray Incorporated (NASDAQ:ARAY) insiders lost US$95k on their investments after a 17% stock drop, despite purchasing US$216.4k worth of stock at an average of US$0.68 over the past year. Director Steven Mayer recently bought US$135k worth of shares, indicating continued confidence, though overall insider ownership is relatively low at 4.8%. The company's recent losses warrant caution for potential investors.
Accuray Inc reports results for the quarter ended March 31 - Earnings Summary
Accuray Inc (ARAY) has reported its financial results for the quarter that ended on March 31. This earnings summary was provided by Refinitiv and Reuters. The article is a brief news update regarding the company's financial performance.
Accuray Incorporated (NASDAQ:ARAY) Q3 2026 Earnings Call Transcript
Accuray Incorporated (NASDAQ: ARAY) reported a Q3 2026 EPS of $-0.09, missing expectations of $-0.05. The company's total revenue was $105 million, down 7% year-over-year, primarily due to geopolitical disruptions in the Middle East and ongoing headwinds in China. Accuray withdrew its financial guidance due to significant unpredictability but remains confident in its transformation plan, which aims to improve operating profitability by approximately $25 million annually.
Accuray: Fiscal Q3 Earnings Snapshot
Accuray Inc. reported a fiscal third-quarter loss of $11.8 million, or 9 cents per share, on revenue of $104.8 million. The company's shares were trading at 49 cents on Wednesday, a decrease from $1.30 a year ago. This report was generated by Automated Insights using data from Zacks Investment Research.
Accuray Incorporated 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:ARAY) 2026-05-07
Accuray Incorporated (ARAY) has published its slide deck in conjunction with its 2026 Q3 earnings call presentation. This article by SA Transcripts highlights the availability of these materials for investors.
[8-K] ACCURAY INC Reports Material Event
Accuray Incorporated (NASDAQ: ARAY) reported weaker fiscal 2026 third-quarter results and withdrew its full-year guidance due to geopolitical uncertainty in the Middle East impacting installations. Total net revenue decreased by 7% to $104.8 million, and the net loss widened to $11.8 million, or $0.09 per share. Despite progress on a transformation plan, the company faces near-term visibility risks.
Accuray: Fiscal Q3 Earnings Snapshot
Accuray Inc. (ARAY) reported a fiscal third-quarter loss of $11.8 million, or 9 cents per share, on revenue of $104.8 million. The company's shares were trading at 49 cents at the close of Wednesday's trading, down from $1.30 a year ago. This financial summary was generated using data from Zacks Investment Research.
Accuray Inc expected to post a loss of 4 cents a share - Earnings Preview
Accuray Inc (ARAY) is expected to announce an earnings loss of 4 cents per share. This forecast is provided as an earnings preview by Refinitiv.
Accuray Incorporated Files Form 8-K Report with SEC Detailing Company Information and Compliance Data
Accuray Incorporated (NASDAQ: ARAY) announced the departure of its Senior Vice President and Chief Operations Officer, Leonel Peralta, effective April 26, 2026. The company specifically stated that the resignation was not due to any disagreements with the company's operations, policies, or board. This executive change was disclosed in a Form 8-K filing with the SEC, and shareholders are advised to monitor future disclosures regarding a new COO appointment.
Operations chief Leonel Peralta exits Accuray (NASDAQ: ARAY) leadership team
Accuray Incorporated announced that Leonel Peralta, Senior Vice President and Chief Operations Officer, departed the company effective April 26, 2026. The company stated that his resignation was not due to any disagreement with Accuray, its Board of Directors, or its operations, policies, or practices. The 8-K filing details this leadership change and includes standard exhibit information.
Accuray to Report Third Quarter Fiscal 2026 Financial Results on May 6, 2026
Accuray Incorporated (NASDAQ: ARAY) announced it will report its third quarter fiscal year 2026 financial results on May 6, 2026. A conference call will be hosted by company management, with dial-in numbers and a live webcast available for investors and interested parties. The company is committed to advancing radiation therapy for various medical conditions.
Accuray (ARAY) to Release Quarterly Earnings on Wednesday
Accuray (NASDAQ:ARAY) is scheduled to release its Q3 2026 earnings after market close on Wednesday, April 29th, with analysts projecting an EPS of ($0.05) and revenue of $111.90 million. In the previous quarter, the medical equipment provider met EPS estimates at ($0.11) and exceeded revenue expectations with $102.24 million, though it continues to operate at a loss. The stock, currently trading around $0.42 with a market cap of approximately $50 million, holds a consensus "Hold" rating from MarketBeat with a $2.00 target price.
Accuray schedules May 6 call for fiscal third-quarter results
Accuray (NASDAQ: ARAY) will report its Q3 fiscal 2026 financial results on May 6, 2026, for the period ending March 31, 2026. The company will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, with replay options available for interested investors. This announcement follows recent efforts by Accuray to implement a transformation plan aimed at improving operating profitability, despite reporting declining revenues in previous quarters.
How many employees work at Accuray?
Accuray, Inc. currently employs 1,028 individuals, according to Revelio Labs data updated in December 2025. The company has experienced a YoY growth rate of -10.2% in employee count. Historical data shows fluctuating employee numbers and active job postings over recent years.
TCW Group discloses 11.5% Accuray (ARAY) stake through 15.5M warrant shares
TCW Group has reported a beneficial ownership of 11.5% in Accuray Inc. (ARAY), amounting to 15,467,952 shares, primarily through warrants. These warrants, issued on December 15, 2025, were part of amendments to a Financing Agreement and have exercise prices ranging from $0.01 to $1.50, expiring on December 15, 2032. The disclosure indicates that no separate consideration was paid for these warrants, and none have been exercised to date, with their purpose being to incentivize agreement to the financing amendments.
CapEx per share of Accuray Incorporated – LSE:0H8I
The article displays the title "CapEx per share of Accuray Incorporated – LSE:0H8I" and indicates that the market is closed with no trades. It provides a structured view for financial information, news, community, technicals, forecasts, seasonals, bonds, and ETFs related to Accuray Incorporated on the London Stock Exchange.
Accuray (NASDAQ: ARAY) SVP Paul Miele submits Form 3 insider ownership
Accuray Inc.'s Senior Vice President and Chief Commercial Officer, Paul Michael Miele, has filed a Form 3, an initial statement of beneficial ownership of securities. This filing officially establishes Miele as a reporting insider for Accuray (ARAY) but does not indicate any specific share transactions or existing holdings. The Form 3 serves to publicly acknowledge new insiders and their initial ownership status, rather than reporting changes in ownership.
Paul Miele named Accuray CCO
Accuray Incorporated has announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele will lead the company's global commercial organization, focusing on transformation, strengthening execution, and enhancing commercial performance. His extensive experience in medical technology, including a commercial turnaround at Johnson & Johnson MedTech, is expected to drive Accuray's long-term value creation and growth in systems and services sales.
Accuray Amends Dedication Capital Consulting Agreement, Cuts Fees
Accuray (ARAY) has amended its consulting agreement with Dedication Capital, an affiliate of director Steven F. Mayer, effective April 1, 2026. The amendment cuts the base consulting fee and minimum cash incentive amounts by 50% and accelerates equity vesting for 916,336 restricted shares and all performance stock awards. These changes, along with an extension of the consulting end date to October 31, 2026, and the vesting of an additional 333,004 restricted shares, are expected to save Accuray at least $362,500.
Accuray amends consulting agreement, reduces fees and modifies equity vesting
Accuray Incorporated has amended its consulting agreement with Dedication Capital, LLC, reducing cash compensation and modifying equity vesting terms, expecting to save at least $362,500. This comes as the medical device company faces a significant debt burden and a recent stock decline, though it recently gained nearly 8%. The agreement extension and vesting changes are part of ongoing financial and corporate adjustments.
Accuray (NASDAQ: ARAY) trims consulting pay and accelerates share vesting
Accuray Incorporated (NASDAQ: ARAY) has amended its Consulting Agreement with Dedication Capital, LLC, significantly reducing consulting fees by 50% and accelerating the vesting of 916,336 Initial Restricted Shares and all PSAs. These changes are expected to generate at least $362,500 in cash savings for the company, while the remaining 333,004 Initial Restricted Shares will vest by October 31, 2026, the new end date of the agreement. This action aims to optimize cash flow and modify equity compensation terms for the consulting relationship.
Accuray Appoints Paul Miele as Senior Vice President and Chief Commercial Officer
Accuray Incorporated (NASDAQ: ARAY) has announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele will lead the company's global commercial organization, bringing nearly two decades of experience in scaling global capital medical device businesses. His expertise in commercial turnarounds, accelerating sales, and unlocking recurring revenue opportunities is expected to strengthen Accuray's commercial performance and long-term value creation.
Accuray Appoints New Chief Commercial Officer
Accuray Incorporated, a leading provider of radiation therapy systems for cancer treatment, has appointed Paul Miele as its new Senior Vice President and Chief Commercial Officer. Miele will lead the company's global commercial strategy, sales operations, and go-to-market initiatives, aiming to accelerate the adoption of Accuray's radiation therapy solutions worldwide. This appointment underscores Accuray's focus on strengthening its commercial capabilities and driving growth in the competitive medical technology sector.
Accuray Appoints Paul Miele as Senior Vice President and Chief Commercial Officer Effective April 6, 2026 11
Accuray Incorporated (NASDAQ: ARAY) has appointed Paul Miele as its new Senior Vice President and Chief Commercial Officer, effective April 6, 2026. This strategic move aims to strengthen the company's commercial leadership, drive revenue growth, and expand market presence. Investors are advised to monitor future communications for details on Mr. Miele's plans and the potential impact on Accuray's financial performance.
Accuray names Paul Miele as chief commercial officer
Accuray Incorporated (NASDAQ:ARAY) has appointed Paul Miele as Senior Vice President and Chief Commercial Officer, effective today. Miele, with two decades of experience in global medical device businesses, will lead Accuray's commercial organization, focusing on sales, marketing, pricing, and strategic partnerships. This announcement follows Accuray's recent financial results, which showed a revenue decline and a Nasdaq listing notice due to non-compliance with the minimum bid price rule, despite an InvestingPro analysis suggesting the stock is undervalued.
Accuray Names Paul Miele Chief Commercial Officer
Accuray has appointed Paul Miele as Senior Vice President and Chief Commercial Officer to enhance its global commercial execution and support long-term growth in radiation therapy markets. Miele brings nearly two decades of experience in scaling capital equipment businesses, aiming to boost sales and monetize Accuray's installed base. Spark, TipRanks' AI Analyst, rates ARAY as Neutral due to weak financial quality, declining revenue, and high leverage, despite positive demand indicators.
Accuray Appoints Paul Miele as Senior Vice President and Chief Commercial Officer
Accuray Incorporated announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele brings extensive global commercial leadership experience from his previous roles at Johnson & Johnson MedTech, Globus Medical, and Intuitive Surgical. He will lead Accuray's global commercial organization, focusing on driving sales growth and strengthening commercial performance for the cancer treatment systems provider.
Accuray recruits J&J MedTech executive to run global sales
Accuray (NASDAQ: ARAY) has appointed Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele, previously with Johnson & Johnson MedTech, will lead Accuray's global commercial strategy, aiming to improve sales execution and drive growth. His background includes a proven track record of reversing revenue declines and achieving double-digit sales growth in medical technology businesses.
New Accuray (NASDAQ: ARAY) CCO to lead global commercial strategy
Accuray Incorporated has appointed Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele will lead the company’s global commercial organization across sales, marketing, pricing, and market access, aiming to strengthen commercial execution and drive systems and services sales growth. This appointment, disclosed in an 8-K filing, is part of Accuray's ongoing transformation to enhance long-term value creation, leveraging Miele's experience in driving commercial turnarounds within complex medical technology businesses.
Accuray (ARAY) SVP Chalke uses 40,000 shares to cover RSU taxes
Accuray Inc. SVP and Chief Commercial Officer Sandeep Chalke had 40,000 shares of common stock withheld by the company. This action was taken to cover tax obligations arising from the vesting of Restricted Stock Units (RSUs) at an implied price of $0.3881 per share. Following this transaction, Chalke directly holds 419,806 shares of Accuray Inc.
Q1 2026 Accuray Inc Earnings Call Transcript
This article provides the edited transcript of Accuray Inc.'s Q1 2026 earnings call. It highlights key positive developments such as the launch of the Stellar product, a 7% increase in service revenue, and a strong order backlog. Conversely, it also addresses negative aspects including a 7% decline in net revenue, a 23% decrease in product revenue, and a significant operating loss and negative adjusted EBITDA for the quarter.
Vanguard (ARAY) amendment shows 0 shares after internal realignment
Vanguard has filed an amendment (Schedule 13G/A) for Accuray Inc (ARAY), reporting 0 shares and 0% beneficial ownership as of March 13, 2026. This change is due to an internal realignment on January 12, 2026, where Vanguard's subsidiaries and business divisions will now report beneficial ownership separately, in accordance with SEC Release No. 34-39538. Vanguard explicitly states it no longer holds beneficial ownership over the securities managed by these disaggregated entities.
If You Invested $1,000 in Accuray Incorp (ARAY)
This article analyzes the historical performance of a $1,000 investment in Accuray Incorp (ARAY) over 1, 5, and 10 years, showing significant losses and underperformance compared to the S&P 500. It also provides an overview of Accuray Incorporated, detailing its radiation oncology solutions, key technologies like CyberKnife and Radixact, strategic transformation, financial reporting, and positioning within the radiation oncology industry.
ARAY SEC Filings - Accuray Incorp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Accuray Incorporated (ARAY) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event reports (8-K), and insider trading forms (Form 4). It highlights how these documents provide insights into the company's financial performance, governance, and key corporate events, with AI-powered summaries to help users quickly grasp the significance of each filing. Recent filings cover topics such as director ownership, quarterly financial results, executive compensation, and equity grants.
Accuray (NASDAQ: ARAY) sets separation terms for chief commercial officer
Accuray Incorporated has finalized a separation agreement with its Senior Vice President and Chief Commercial Officer, Sandeep Chalke, ahead of his March 31, 2026 departure. The agreement includes the vesting of equity awards due on May 31, 2026, a lump-sum cash payment of $459,000, and a pro-rated fiscal 2026 bonus. This arrangement replaces previous severance terms and includes a general release of claims.
Book value per share of Accuray Incorporated – BX:XEJ
This article displays the book value per share for Accuray Incorporated (BX:XEJ). It is a financial data point available on TradingView, with specific values for different periods. The article confirms that the market for this particular stock is currently closed.
Accuray (NASDAQ: ARAY) COO exercises RSUs, uses shares to cover tax
Accuray's SVP and COO, Leonel Peralta, exercised 83,723 restricted stock units on February 28, 2026, receiving common shares at $0.00 each. To cover tax withholding obligations, 28,969 common shares were withheld by the company at $0.55 per share. Following these transactions, Peralta directly owns 54,754 shares of Accuray common stock.
ACCURAY INC SEC Filing - Form EFFECT
ACCURAY INC (ARAY) has filed an EFFECT form with the SEC, indicating the effectiveness of its S-3 Shelf Registration Statement as of February 27, 2026, at 9:00 A.M. This filing is deemed neutral in both impact and sentiment by Rhea-AI. The company's recent news includes reporting Q2 2026 financial results and announcing a strategic transformation plan.
7.00M shares registered for resale as ARAY (NASDAQ: ARAY) lenders hold warrants
Accuray Incorporated (NASDAQ: ARAY) has filed a prospectus registering 7,000,516 shares of common stock for resale by existing stockholders. These shares are issuable upon the exercise of warrants that were previously issued to lenders as part of a Loan Amendment. Accuray will not receive proceeds from the resale of these shares but will benefit from any cash exercise of the warrants.
ARAY Technical Analysis & Stock Price Forecast
Accuray Inc (ARAY) is currently exhibiting a "Strong Sell" technical sentiment based on an analysis of 11 technical signals, with 1 indicating buy and 10 indicating sell. The stock is trading below its 60-day and 200-day moving averages, and key indicators like MACD also suggest a sell signal. While the RSI is neutral, the overall technical outlook points to bearish momentum for ARAY.
Accuray (ARAY) files S-3 to register 7.0M warrant shares for lender resale
Accuray Inc. (ARAY) has filed an S-3 registration statement to allow certain lending investors to resell 7,000,516 shares of common stock. These shares are issuable upon the exercise of Super Premium, Premium, and Penny Warrants, previously granted in connection with an amendment to Accuray's senior secured Financing Agreement. Accuray will not receive proceeds from the resale of these shares, but would receive cash if the warrant holders choose to exercise them for cash.
